Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of Golcadomide in Severe Renal Impairment and End-Stage Renal Disease
NCT07763418Phase 1Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial of golcadomide in lymphoma (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed concentration, Time of maximum observed plasma concentration and 2 more. Started Sep 2026; status: recruiting.
02
Drugs
golcadomide
03
Conditions
lymphoma
Beyond the preview
Go deeper on NCT07763418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07763418.